Q: how can we evaluate anticoagulants in a comprehensive way to help select the right drug for clinical use?
Answer: the choice of anticoagulant drugs in clinical treatment should strictly follow the drug indications, evidence and treatment guidelines. For example, of the three low-molecular-weight heparins currently used in the clinic, only kexer can be used for the prevention of VTE and the treatment of pulmonary embolism (PE) in medical patients. The other two drugs do not have these two indications.
In addition to the comprehensive evaluation of physicochemical properties and physicochemical properties of drugs, clinical evaluation should also be paid attention to. The scientific method for clinical evaluation of drugs is high-quality evidence-based medical evidence, not individual cases. Only drugs with reliable efficacy and safety proved by a large number of studies and clinical practice can be used in the treatment of clinical patients. As we can see, kexel ® was the first low molecular weight heparin approved by the FDA in 1987, so the clinical evidence is the most comprehensive of all low molecular weight heparins, and high-quality clinical studies have been conducted in patients with a variety of specific disease subtypes. For example, the familiar ESSENCE and TIM1 11B studies promote guidelines that recommend type IA treatment of UA/NSTEMI with xai ®. The STEEPLE study confirmed the efficacy and safety of kexai ® in patients with PCI. A landmark study in the STEMI field, EXTRACT - TIMI25, prompted kesai ® to obtain FDA approval for the treatment of STEMI.